Paget's Disease of Bone

Disclaimer: > [!WARNING] Medical Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Medical guidelines and best practices change rapidly; users should verify information with current local protocols.

1. Overview

Paget's Disease of Bone (Osteitis Deformans) is a chronic, progressive disorder of bone remodelling characterised by focal areas of excessive and disorganised bone turnover. [1,2]

The disease involves a pathological cascade: excessive osteoclastic bone resorption followed by compensatory but chaotic osteoblastic bone formation, resulting in structurally abnormal bone that is enlarged, hypervascular, and mechanically weak. [3] The affected bone has a characteristic "mosaic" or "jigsaw puzzle" pattern on histology due to irregular cement lines.

While most patients remain asymptomatic, the disease can cause significant morbidity through bone pain, deformity, pathological fractures, neurological compression syndromes, and rare but devastating complications such as malignant transformation to osteosarcoma. [4]

Paget's disease is the second most common metabolic bone disease after osteoporosis in individuals over 55 years. [5] The advent of potent bisphosphonate therapy, particularly intravenous zoledronic acid, has revolutionised management and can provide prolonged disease remission. [6]

---

2. Epidemiology

Prevalence and Geographic Distribution

Paget's disease shows striking geographic variation, being common in certain populations and virtually absent in others. [7,8]

Demographic Features

• Age: Rare before 40 years; prevalence increases with age, peaking in the 7th-8th decades. [10]
• Sex: Male predominance (M:F ratio approximately 3:2). [11]
• Genetic factors: 15-30% have positive family history. [12]
• Temporal trends: Declining prevalence and severity observed over past 30 years, particularly in UK and New Zealand. [13,14]

Risk Factors

1. Genetic susceptibility:
   • SQSTM1 (Sequestosome 1) gene mutations in 30-50% of familial cases [15]
   • Other susceptibility loci identified via GWAS studies
2. Environmental factors:
   • Viral hypothesis (paramyxovirus) - controversial and not proven [16]
   • Possible association with childhood residence in endemic areas
3. Family history: 10-fold increased risk in first-degree relatives [12]

---

3. Aetiology & Pathophysiology

Molecular and Cellular Mechanisms

The fundamental defect in Paget's disease lies in the osteoclast. [17]

Primary Osteoclastic Abnormality

1. Osteoclast morphology:

   • Pagetic osteoclasts are abnormally large and contain up to 100 nuclei (normal: 3-5)
   • Increased numbers of nucleoli and characteristic nuclear inclusions
   • Enhanced sensitivity to RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) [18]

2. Excessive bone resorption:

   • Increased osteoclast recruitment and activity
   • Upregulation of RANK signalling pathway
   • Accelerated bone turnover (up to 10-20 times normal rate) [3]

Genetic Factors

SQSTM1/p62 mutations: [15,19]

• Most common genetic cause (accounts for 30-50% of familial cases)
• SQSTM1 encodes p62 protein - involved in RANK/NF-κB signalling
• Mutations lead to hyperactivation of NF-κB pathway
• Results in enhanced osteoclast formation and survival

Other susceptibility genes:

• VCP (Valosin-containing protein)
• TNFRSF11A (RANK gene)
• Optic atrophy 1 (OPA1)
• Multiple loci identified through genome-wide association studies [20]

Secondary Osteoblastic Response

1. Compensatory bone formation:

   • Coupling factors released during resorption stimulate osteoblasts
   • Rapid, disorganised bone deposition
   • Formation of "woven" bone (non-lamellar, randomly oriented collagen fibres) [21]

2. Structural abnormalities:

   • Mosaic pattern: Irregular cement lines creating jigsaw appearance on histology
   • Increased bone vascularity (arteriovenous shunts)
   • Enlarged bone with coarse trabecular architecture
   • Mechanically weak despite increased density [3]

Three Phases of Disease

Exam Detail: Advanced Pathophysiology - Viva Points:

The NF-κB signalling pathway is central to Paget's disease pathogenesis:

• RANK-RANKL binding activates NF-κB via multiple adaptor proteins
• SQSTM1/p62 mutations impair ubiquitin-mediated degradation of signalling intermediates
• Results in constitutive NF-κB activation and enhanced osteoclastogenesis [19]

Why is calcium normal?

• Despite massive bone turnover, resorption and formation are coupled
• Calcium released during resorption is immediately re-incorporated during formation
• Parathyroid function remains intact
• Hypercalcaemia only occurs with immobilisation (uncoupling of processes)

Increased vascularity mechanism:

• Pagetic bone has 2-3 fold increased blood flow [22]
• Arteriovenous shunts develop within medullary bone
• Can lead to high-output cardiac failure in severe polyostotic disease (> 35% skeleton involved)
• Explains warmth on palpation and increased risk of bleeding during surgery

---

4. Clinical Presentation

Symptom Spectrum

Approximately 70-80% of patients are asymptomatic and diagnosed incidentally through elevated ALP or radiological findings. [23]

Symptomatic Disease Manifestations

Bone Pain (most common symptom when present):

• Character: Deep, boring, unrelenting ache
• Pattern: Worse with weight-bearing but often present at rest
• Mechanisms:
  • Microfractures in weakened bone
  • Vascular distension and pressure within bone
  • Secondary osteoarthritis in adjacent joints
  • Periosteal stretching from bone expansion
• Red flag: Sudden worsening or severe focal pain suggests pathological fracture or malignant transformation [4]

Bone Deformity: [24]

Neurological Complications: [25]

1. Hearing loss (most common neurological complication):

   • Sensorineural: Compression of cochlear nerve in petrous temporal bone
   • Conductive: Ossicular chain involvement or fixation
   • Mixed: Combination of both mechanisms
   • Present in 30-50% of patients with skull involvement

2. Spinal complications:

   • Lumbar stenosis from vertebral expansion
   • Radiculopathy from nerve root compression
   • Rarely, spinal cord compression (especially cervical/thoracic)

3. Other cranial nerve involvement:

   • Optic nerve compression (visual loss)
   • Trigeminal neuralgia
   • Facial nerve palsy

Cardiovascular: [22]

• High-output cardiac failure: Rare (less than 1%) but classic complication
• Mechanism: Extensive arteriovenous shunting in hypervascular pagetic bone
• Typically requires > 35-40% skeletal involvement
• Presents with features of congestive cardiac failure but high cardiac output

Fractures:

• Pathological fractures occur in 10-30% of patients [26]
• "Chalk-stick" fractures - transverse fractures through pagetic bone
• Commonly affect femur, tibia, humerus
• Delayed union and non-union common

Sites of Involvement

Common sites (in order of frequency): [23]

1. Pelvis (70% of cases)
2. Lumbar spine (58%)
3. Femur (55%)
4. Thoracic spine (45%)
5. Skull (42%)
6. Tibia (32%)
7. Humerus (31%)

Distribution patterns:

• Monostotic (15-35%): Single bone involvement
• Polyostotic (65-85%): Multiple bones affected
• Disease remains localised to initially affected sites (does not "spread")

---

5. Clinical Examination

Systematic Approach

General Inspection:

• Assess gait (bowing deformities, leg length discrepancy)
• Observe posture (kyphosis, spinal deformity)
• Note skeletal proportions (disproportionate limb lengths)

Look:

1. Skull: Enlargement, frontal bossing, asymmetry
2. Long bones: Anterior tibial bowing (sabre shin), femoral bowing
3. Spine: Kyphosis, loss of lumbar lordosis
4. Skin: Look for scars from previous fractures or surgeries

Feel:

1. Increased warmth over affected bone (classic finding) [3]
   • Due to hypervascular bone and arteriovenous shunting
   • Compare affected vs unaffected limb
2. Bone enlargement: Palpable thickening of tibia, skull
3. Tenderness: May be present over active lesions

Move:

1. Range of motion: Often restricted in adjacent joints
2. Secondary osteoarthritis: Hip and knee most commonly affected [27]
3. Neurological examination:
   • Hearing assessment (Rinne and Weber tests)
   • Cranial nerve examination if skull involvement
   • Peripheral nerve examination if spinal involvement

Special Tests:

• Measure leg lengths (true and apparent)
• Assess for spinal stenosis (neurogenic claudication)
• Cardiovascular examination (signs of high-output failure in extensive disease)

---

6. Differential Diagnosis

Key Differentials with Distinguishing Features

Clinical Scenarios Requiring Differentiation

Isolated Raised ALP:

1. Paget's disease: Localised bone involvement, normal liver function
2. Liver disease: Elevated GGT, abnormal transaminases
3. Bone metastases: History of malignancy, multiple sites on imaging
4. Osteomalacia: Low vitamin D, low phosphate, generalised osteopenia

Bone Pain in Elderly:

1. Paget's disease: Deep, boring pain; warm bone; very high ALP
2. Osteoarthritis: Mechanical pain, crepitus, joint-line tenderness
3. Osteoporosis: Usually painless unless fracture
4. Malignancy: Constitutional symptoms, progressive, multifocal

Skull Thickening:

1. Paget's disease: Cotton wool appearance, isolated ALP elevation
2. Fibrous dysplasia: Ground glass, younger age
3. Acromegaly: Other features of GH excess
4. Hyperostosis frontalis interna: Benign, incidental

---

7. Investigations

Biochemistry

Alkaline Phosphatase (ALP): [28]

• Hallmark biochemical abnormality
• Reflects extent and activity of disease
• Levels correlate with:
  • Total skeletal involvement
  • Disease activity (bone formation rate)
  • Response to treatment
• Levels:
  • "Mild disease: 130-300 IU/L"
  • "Moderate: 300-1000 IU/L"
  • "Severe: > 1000 IU/L (can exceed 3000-5000 IU/L)"
• Bone-specific ALP: More specific marker when liver disease suspected

Calcium and Phosphate:

• Usually normal in active disease (essential for diagnosis) [28]
• Hypercalcaemia only occurs in specific circumstances:
  • Immobilisation (uncoupling of resorption/formation)
  • Concurrent primary hyperparathyroidism
  • Prolonged bed rest or fracture
• Hypocalcaemia: May occur post-treatment ("hungry bone syndrome")

Bone Turnover Markers:

1. Formation markers:
   • Procollagen type 1 N-terminal propeptide (P1NP)
   • Bone-specific alkaline phosphatase (BSAP)
2. Resorption markers:
   • N-telopeptide (NTX)
   • C-telopeptide (CTX)
   • Deoxypyridinoline (DPD) - urinary

Other blood tests:

• Vitamin D: Exclude deficiency before bisphosphonate therapy
• Renal function: Essential before bisphosphonate use
• Serum protein electrophoresis: If myeloma suspected

Radiological Investigations

Plain Radiographs: [29]

Isotope Bone Scan (Technetium-99m MDP): [30]

• Most sensitive imaging modality for detecting extent of disease
• Shows increased uptake ("hot spots") at sites of active disease
• Indications:
  • Define extent of skeletal involvement
  • Detect subclinical sites
  • Pre-operative planning
  • Monitoring response to treatment
• Limitations:
  • Not specific (also positive in fracture, malignancy, infection)
  • Cannot distinguish Paget's from complications

Advanced Imaging:

1. MRI: [31]

   • Indications: Suspected complications (malignancy, spinal stenosis)
   • Findings: Variable signal intensity, rule out soft tissue mass
   • Useful for neural compression assessment

2. CT:

   • Better bone detail than X-ray
   • Pre-operative assessment
   • Evaluation of fractures or deformity

3. PET-CT:

   • Role in suspected sarcomatous transformation
   • Differentiate active Paget's from malignancy

Histopathology

Bone biopsy - rarely required but shows pathognomonic features: [21]

• Mosaic pattern: Irregular cement lines creating jigsaw appearance
• Large, multinucleated osteoclasts (up to 100 nuclei)
• Increased bone vascularity
• Woven bone architecture (non-lamellar)
• Indication: When diagnosis uncertain or malignancy suspected

Exam Detail: Investigation Interpretation Pearls:

When ALP is elevated, always check:

1. Liver function tests (exclude hepatic source)
2. Bone-specific ALP or isoenzyme analysis
3. Calcium and phosphate (must be normal for Paget's)

Isotope bone scan patterns:

• Paget's: Intense, homogeneous uptake in entire affected bone
• Metastases: Multiple focal lesions, usually smaller and more discrete
• Fracture: Linear increased uptake

Red flags on imaging:

• Soft tissue mass (suspect osteosarcoma)
• Bone destruction beyond advancing edge
• Cortical break with displacement
• Periosteal reaction or sunburst pattern

Interpreting treatment response:

• ALP should fall by > 75% after zoledronic acid [6]
• Normalisation occurs in 60-90% of patients
• Reduction usually maximal at 6 months
• If inadequate response, consider compliance, diagnosis, or bisphosphonate resistance

---

8. Classification & Staging

Disease Extent

Monostotic vs Polyostotic: [23]

• Monostotic (15-35%): Single bone involved
• Polyostotic (65-85%): Multiple bones affected

Severity Assessment: No universally accepted staging system, but severity assessed by:

1. Percentage of skeleton involved:

   • Limited: less than 10% of skeleton
   • Moderate: 10-35%
   • Extensive: > 35% (risk of high-output failure)

2. ALP level (indirect measure of total disease activity)

3. Symptom burden and functional impact

Site-Specific Classification

Skull involvement severity: [25]

• Grade I: Isolated calvarial involvement
• Grade II: Calvarial + skull base
• Grade III: Skull base with cranial nerve compression
• Grade IV: Basilar invagination

---

9. Management

Indications for Treatment

Not all patients require treatment. [32] Treatment indicated if:

Observation only: [34]

• Asymptomatic monostotic disease
• Isolated ALP elevation without symptoms
• Burned-out sclerotic phase
• Sites unlikely to cause complications

Pharmacotherapy

First-Line: Bisphosphonates

Zoledronic Acid (Aclasta®): [6,35]

• Dose: 5mg IV infusion over 15-30 minutes (single dose)
• Efficacy:
  • 89-96% achieve therapeutic response (ALP reduction > 75%)
  • 60-89% achieve normalisation of ALP
  • "Effect duration: Median 6.5 years (range 2-10 years)"
  • Superior to all oral bisphosphonates [6]
• Advantages:
  • Single dose (excellent compliance)
  • Prolonged remission
  • Rapid ALP reduction
• Monitoring:
  • ALP at 3, 6, 12 months
  • Renal function and calcium pre-treatment and 2 weeks post
  • Consider re-treatment if relapse (ALP rise > 25% from nadir)

Risedronate: [36]

• Dose: 30mg oral daily for 2 months
• Alternative if zoledronic acid contraindicated/refused
• Less effective than zoledronic acid (60% normalisation rate)

Alendronate:

• Dose: 40mg oral daily for 6 months
• Less commonly used due to prolonged course

Pamidronate:

• Dose: 60mg IV every 3 months for multiple doses
• Alternative parenteral option

Pre-treatment Requirements

Before ANY bisphosphonate: [32]

1. Check vitamin D: Correct deficiency (target > 50 nmol/L)
2. Check calcium: Ensure adequate intake (1200mg/day)
3. Renal function: eGFR > 35 mL/min for zoledronic acid
4. Dental assessment: If high-risk for osteonecrosis of jaw (ONJ)
5. Hydration: Ensure adequate hydration (especially for IV therapy)

Adverse Effects of Bisphosphonates

Alternative Therapies (Historical)

Calcitonin: [37]

• Rarely used now (less effective than bisphosphonates)
• Dose: 50-100 units SC 3 times weekly
• Role: Bisphosphonate-intolerant patients
• Limitation: Tachyphylaxis develops, injectable, expensive

Denosumab:

• Emerging evidence in bisphosphonate-resistant cases [38]
• Not licensed for Paget's disease
• Use reserved for refractory cases

Analgesic Therapy

Pain management adjuncts:

1. Paracetamol: First-line for mild pain
2. NSAIDs: Effective for bone pain and secondary OA
3. Opioids: Reserved for severe pain or malignancy
4. Neuropathic agents: Gabapentin/pregabalin for radiculopathy

Surgical Management

Orthopaedic interventions: [33]

Surgical principles in Paget's disease:

• Pre-treat with bisphosphonates 3-6 months before elective surgery [33]
• Expect increased blood loss (hypervascular bone)
• Type and cross-match extra units
• Consider cell salvage techniques
• Higher non-union and delayed union rates
• May require larger/custom implants due to bone expansion

Neurosurgical intervention:

• Spinal decompression for myelopathy
• Nerve root decompression for radiculopathy
• Rarely, cranial nerve decompression

Special Populations

Pregnancy:

• Bisphosphonates contraindicated (category D)
• Defer treatment until after delivery and breastfeeding
• Calcitonin is category C (use if essential)

Renal Impairment:

• eGFR 35-60: Slower infusion rate for zoledronic acid
• eGFR less than 35: Avoid zoledronic acid; consider risedronate with dose adjustment

Elderly/Frail:

• Ensure adequate calcium/vitamin D before treatment
• Monitor for acute phase reaction (may be more severe)
• Careful fluid balance with IV bisphosphonates

---

10. Complications

Fractures

Pathological fractures: [26]

• Occur in 10-30% of patients
• Sites: Femur > tibia > humerus
• Type: "Chalk-stick" fractures (transverse, through pagetic bone)
• Characteristics:
  • Often minimal trauma
  • Delayed union and non-union common
  • High re-fracture rate
• Management:
  • Surgical fixation often required
  • Bisphosphonate therapy to enhance healing
  • Prolonged rehabilitation

Malignant Transformation: Osteosarcoma

Rare but devastating complication (less than 1% of Paget's cases). [4,39]

Red flag signs:

• Sudden worsening of bone pain
• New soft tissue swelling or mass
• Rapid increase in ALP (> 50% rise)
• Bone destruction beyond advancing edge on imaging

Osteoarthritis (Secondary)

Most common complication (20-40% of patients): [27]

• Mechanism: Abnormal biomechanics from bone deformity
• Commonly affects: Hip > knee > spine
• Occurs adjacent to pagetic bone (not within it)
• Management: Standard OA treatment ± joint replacement

Neurological Complications

Hearing loss: [25]

• Frequency: 30-50% with skull involvement
• Usually irreversible (even with treatment)
• Sensorineural > conductive > mixed
• Cochlear implants may be considered in select cases

Spinal stenosis:

• Lumbar > thoracic > cervical
• Presents as neurogenic claudication or myelopathy
• May require surgical decompression

Basilar invagination:

• Rare but serious (skull base Paget's)
• Compression of brainstem and cranial nerves
• May require occipitocervical fusion

Cardiovascular Complications

High-output cardiac failure: [22]

• Rare (less than 1% of cases)
• Requires > 35-40% skeletal involvement
• Mechanism: Extensive AV shunting in hypervascular pagetic bone
• Features: Elevated cardiac output, wide pulse pressure, warm extremities
• Management: Bisphosphonates (reduce skeletal blood flow) + standard heart failure therapy

Hypercalcaemia

Immobilisation hypercalcaemia: [40]

• Occurs when patient becomes immobilised (bed rest, fracture)
• Mechanism: Uncoupling of bone resorption and formation
• Prevention: Early mobilisation, bisphosphonate therapy, hydration
• Management: IV fluids, bisphosphonates, calcitonin if severe

Bleeding

Increased operative bleeding: [33]

• Hypervascular bone has increased blood flow
• Significant issue during orthopaedic surgery
• Prevention: Pre-operative bisphosphonate therapy (3-6 months before)
• May require cell salvage or increased transfusion

---

11. Prognosis & Outcomes

Natural History

Untreated disease:

• Chronic, slowly progressive
• Disease remains localised to initially affected bones (does not "spread")
• Progression rate variable and unpredictable
• Majority remain asymptomatic or minimally symptomatic [23]

Treatment Outcomes

Bisphosphonate therapy: [6,35]

• ALP normalisation: 60-90% with zoledronic acid
• Pain relief: 60-80% experience significant reduction
• Remission duration: Median 6.5 years after single dose zoledronic acid
• Quality of life: Significant improvement in pain and function scores
• Fracture risk: Limited evidence for reduction (PRISM trial showed no significant fracture risk reduction with intensive ALP suppression) [41]

PRISM Trial Key Findings: [41]

• Intensive ALP suppression did NOT reduce fracture risk vs symptomatic management
• DID improve bone pain scores
• Challenged strategy of treating to normalise ALP in asymptomatic patients
• Current approach: Treat symptomatic patients, observe asymptomatic

Life Expectancy

Overall: [42]

• Normal life expectancy if no malignant transformation
• Increased standardised mortality ratio due to:
  • Cardiovascular disease
  • Malignancy (not just osteosarcoma)
  • Fracture-related complications

Prognostic Factors

Favourable:

• Monostotic disease
• Low ALP levels
• Sclerotic (burned-out) phase
• Response to bisphosphonate therapy

Unfavourable:

• Polyostotic disease with extensive involvement
• Skull base or spinal involvement
• Very high ALP (> 1000 IU/L)
• Development of osteosarcoma (survival less than 10% at 5 years)

---

12. Prevention & Screening

Primary Prevention

No established primary prevention strategies:

• Genetic counselling for families with SQSTM1 mutations
• No environmental modifications proven effective
• Viral hypothesis unproven

Screening Recommendations

Routine population screening: Not recommended [32]

Family screening: [43]

• First-degree relatives of patients with Paget's disease
• Consider screening from age 40:
  • Serum ALP
  • Radiographs if ALP elevated or symptoms
  • Genetic testing for SQSTM1 mutations (research setting)

Follow-up monitoring:

• Treated patients: ALP every 3-6 months initially, then annually
• Asymptomatic patients: Annual ALP, clinical review
• Imaging: Only if symptoms or concern for complications

---

13. Key Guidelines & Evidence

Major Society Guidelines

1. Endocrine Society Clinical Practice Guideline (2014): [32]

   • Comprehensive management recommendations
   • Emphasizes treatment of symptomatic disease
   • Zoledronic acid as first-line therapy
   • Against routine treatment of asymptomatic patients solely to normalise ALP

2. Paget's Association (UK) Guidelines (2016):

   • Practical management advice
   • Patient resources and support

3. American College of Rheumatology:

   • Similar recommendations to Endocrine Society
   • Emphasizes multidisciplinary approach

Landmark Trials

PRISM Trial (Tan et al., 2017): [41]

• Design: Randomized trial of intensive vs symptomatic management
• Finding: Intensive ALP suppression did NOT reduce fracture risk
• Impact: Changed practice - less aggressive treatment of asymptomatic patients

Zoledronic Acid vs Risedronate (Reid et al., 2005): [6]

• Design: Head-to-head comparison
• Finding: Zoledronic acid superior (96% vs 74% therapeutic response)
• Impact: Established zoledronic acid as first-line therapy

PRISM-EZ Trial (Tan et al., 2017): [44]

• Confirmed long-term efficacy of zoledronic acid
• Median response duration 6.5 years

---

14. Exam-Focused Content

Common MRCP/FRACP Exam Questions

Viva/Clinical scenarios:

1. "A 68-year-old presents with an isolated raised ALP of 800. What is your differential and how would you investigate?"
2. "How would you distinguish Paget's disease from osteomalacia biochemically?"
3. "What is the mechanism of hearing loss in Paget's disease of the skull?"
4. "Describe the management of a patient requiring hip replacement with Paget's disease of the pelvis"
5. "What are the indications for treating Paget's disease?"

SBA/MCQ themes:

• Biochemical profile (isolated raised ALP, normal Ca/PO4)
• Radiological appearances (cotton wool skull, sabre tibia)
• First-line treatment (zoledronic acid)
• Complications (osteosarcoma, hearing loss)
• Genetic associations (SQSTM1)

Viva Opening Statement

Viva Point: Opening statement:

"Paget's disease of bone, also known as osteitis deformans, is a chronic disorder of excessive and disorganised bone remodelling, affecting 5-8% of adults over 55 in the UK. It is characterised by excessive osteoclastic bone resorption followed by chaotic osteoblastic bone formation, resulting in structurally weak, expanded bone with a characteristic mosaic pattern on histology."

Key facts to mention:

1. Epidemiology: Second most common metabolic bone disease; 5-8% prevalence in UK adults > 55; male predominance
2. Genetics: SQSTM1 mutations in 30-50% of familial cases
3. Biochemistry: Markedly elevated ALP with normal calcium and phosphate (pathognomonic)
4. Classic radiological findings: Cotton wool skull, sabre tibia, picture-frame vertebrae
5. First-line treatment: Zoledronic acid 5mg IV (single dose); 89-96% therapeutic response; median remission 6.5 years
6. Complications: Osteosarcoma (less than 1% but very poor prognosis), pathological fractures (10-30%), secondary OA, hearing loss

Common Exam Mistakes

❌ Mistakes that fail candidates:

• Failing to mention normal calcium/phosphate (essential for diagnosis)
• Suggesting bisphosphonates without checking vitamin D and calcium first
• Missing osteosarcoma as a complication
• Not knowing mechanism of hearing loss (cranial nerve VIII compression)
• Recommending routine treatment of asymptomatic patients
• Confusing with osteomalacia (which has LOW phosphate)
• Not recognising that disease doesn't "spread"
• remains localised
• Stating Paget's causes hypercalcaemia (only with immobilisation)

✅ What examiners want to hear:

• "Isolated raised ALP with normal calcium and phosphate"
• "Most patients are asymptomatic - 70-80%"
• "Zoledronic acid is first-line - single 5mg IV dose"
• "Check vitamin D and correct before bisphosphonates"
• "PRISM trial showed intensive therapy doesn't reduce fractures"
• "Osteosarcoma is rare (less than 1%) but has very poor prognosis"
• "Disease remains localised to initially affected bones"

Model Answers

Q: A 72-year-old man has an ALP of 850 IU/L. Calcium, phosphate, and liver function are normal. What is your approach?

A: "This presentation of an isolated raised alkaline phosphatase with normal calcium, phosphate, and liver function is highly suggestive of Paget's disease of bone. My approach would be systematic:

Initial assessment:

• Take a detailed history: bone pain, deformity, increasing hat size, hearing loss, family history
• Examine for bone deformity, warmth over bones, hearing assessment
• Exclude other causes: check bone-specific ALP to confirm skeletal source; review medications

Investigations:

• Plain radiographs of suspected sites (skull, pelvis, long bones) looking for characteristic features: cotton wool skull, thickened cortices, lytic wedge
• Isotope bone scan to define extent of skeletal involvement
• Baseline renal function and vitamin D levels

Management: If asymptomatic with incidental finding, I would discuss observation vs treatment. The PRISM trial showed that intensive ALP suppression doesn't reduce fracture risk in asymptomatic patients.

However, I would recommend treatment with zoledronic acid 5mg IV if:

• Symptomatic bone pain
• Skull base involvement (risk of cranial nerve compression)
• Extensive lytic lesions in weight-bearing bones
• Pre-operative (if surgery planned)

Before treatment, I would ensure:

• Vitamin D > 50 nmol/L (correct if deficient)
• Adequate calcium intake (1200mg/day)
• eGFR > 35 mL/min
• Dental assessment if high-risk for ONJ

Follow-up:

• Monitor ALP at 3, 6, 12 months
• Expect > 75% reduction; 60-90% achieve normalisation
• Median remission duration 6.5 years with zoledronic acid
• Educate regarding red flag symptoms (sudden severe pain - suspect fracture or osteosarcoma)"

Q: What are the neurological complications of Paget's disease?

A: "The neurological complications of Paget's disease result from direct compression by expanded pagetic bone:

Cranial nerve complications (skull involvement):

1. Hearing loss (most common neurological complication):

   • Affects 30-50% with skull involvement
   • Mechanism: Sensorineural (CN VIII compression in petrous temporal bone), conductive (ossicular fixation), or mixed
   • Usually irreversible despite treatment

2. Other cranial nerves:

   • CN II: Optic nerve compression causing visual loss
   • CN V: Trigeminal neuralgia
   • CN VII: Facial nerve palsy

Spinal complications:

1. Spinal stenosis (lumbar most common):

   • Mechanism: Vertebral expansion narrowing spinal canal
   • Presents as neurogenic claudication
   • May require decompressive surgery

2. Radiculopathy:

   • Nerve root compression from vertebral expansion
   • L5/S1 most common

3. Myelopathy (rare):

   • Spinal cord compression
   • More common in thoracic spine
   • Requires urgent neurosurgical assessment

Basilar invagination:

• Skull base Paget's causing upward migration of odontoid
• Brainstem compression
• May require occipitocervical fusion

Management involves bisphosphonate therapy and surgical decompression in severe cases."

---

15. Patient & Layperson Explanation

What is Paget's Disease?

Simple explanation:

Your bones are living tissue that is constantly being renewed - like a building that is being renovated room by room. Old bone is removed by "demolition" cells called osteoclasts, and new bone is laid down by "builder" cells called osteoblasts. Normally, this process is perfectly balanced and controlled.

In Paget's disease, this renovation process goes into overdrive in certain bones. The "demolition crew" works too fast, breaking down bone rapidly. The "builder crew" then panics and rushes to lay down new bone, but they work in a disorganised, messy way.

The result is bone that is bigger and denser than normal, but actually weaker and more prone to problems. It's like a wall that's been built with bricks laid in random directions - it might look thick and strong, but it's structurally unsound.

Common Questions

Q: Is it cancer? A: No. Paget's disease is NOT cancer. It is a benign condition of abnormal bone remodelling. However, in very rare cases (less than 1 in 100 patients), the abnormal bone cells can transform into a bone cancer called osteosarcoma. This is why monitoring is important.

Q: Why is my head getting bigger? A: The skull is a common place for Paget's disease to occur. As the bone thickens and expands, it can make your hat feel tight. Many patients notice they need a bigger hat size. The skull expansion can also put pressure on nerves, particularly the nerve to your ear, which can cause deafness.

Q: Will it spread to other bones? A: No. Paget's disease stays in the bones it first affects. It doesn't spread to new bones like cancer does. If you have it in your pelvis and skull, it will stay in those bones and won't move to your arms or legs.

Q: Do I need treatment? A: Not everyone with Paget's disease needs treatment. In fact, about 70-80% of people have no symptoms at all and are diagnosed by chance when blood tests show a high alkaline phosphatase level.

You may need treatment if you have:

• Bone pain from the Paget's disease
• Bones that are becoming deformed
• The disease is in your skull causing hearing problems
• You're having surgery on an affected bone
• You have extensive disease affecting many bones

Q: What is the treatment? A: The main treatment is a medication called zoledronic acid (brand name Aclasta). This is given as a drip into your vein (IV infusion) and takes about 15-30 minutes. The remarkable thing is that one single dose can control the disease for many years - on average about 6-7 years.

The medication works like a brake on the "demolition crew", slowing down the bone breakdown and allowing everything to return to a more normal pace.

Before you have the treatment, we need to make sure:

• Your vitamin D level is good (we give supplements if it's low)
• Your kidneys are working well
• You're well hydrated

After the infusion, about 30-50% of people get flu-like symptoms (fever, aches) for 1-3 days. This is normal and can be managed with paracetamol.

Q: What are the side effects? A: Most side effects are mild:

• Flu-like symptoms for 1-3 days after the infusion (common)
• Temporary drop in calcium levels (we give calcium and vitamin D tablets)
• Rarely, jaw problems if you have dental disease (we check your teeth first)

Q: Will my bones return to normal? A: The treatment stops the abnormal bone turnover and can significantly reduce pain, but it won't reverse deformity that has already occurred. Think of it like pressing the pause button - it stops things getting worse, but doesn't rewind the clock.

Q: Can I still exercise? A: Yes! Staying active is important. However, if you have bone deformity or weakening, you may need to avoid high-impact activities that could cause fractures. Your doctor can advise on safe activities based on which bones are affected.

Q: Is it hereditary? A: There is a genetic component. About 15-30% of people with Paget's disease have a family member with the condition. If you have Paget's disease, your children and siblings have a higher risk. We sometimes recommend they have a blood test (alkaline phosphatase) from age 40 onwards, especially if they develop symptoms.

Q: What should I watch out for? A: Contact your doctor urgently if you develop:

• Sudden, severe bone pain (could indicate a fracture or, rarely, cancer)
• A lump or swelling near the affected bone
• Sudden worsening of hearing
• Symptoms of high calcium (extreme thirst, confusion, nausea)

Q: Will I have a normal life expectancy? A: Yes. With modern treatment, most people with Paget's disease have a normal life expectancy. The key is monitoring and treating complications if they arise.

---

16. Clinical Pearls & High-Yield Facts

Clinical Pearl: For MRCP/FRACP exams:

1. "Isolated raised ALP + normal Ca/PO4" = Paget's disease until proven otherwise

2. SQSTM1 mutation = most common genetic association (30-50% familial cases)

3. Zoledronic acid 5mg IV = first-line; single dose; 6.5 year remission

4. Cotton wool skull = pathognomonic radiological sign (mixed lytic-sclerotic)

5. Sabre tibia = anterior tibial bowing - classic deformity

6. Osteosarcoma risk less than 1% but 5-year survival less than 10% (devastating)

7. PRISM trial: Intensive Rx did NOT reduce fractures (changed practice)

8. Hypercalcaemia only with immobilisation (not in active disease)

9. High-output heart failure requires > 35% skeletal involvement

10. Disease does NOT spread - remains in initially affected bones

11. 70-80% asymptomatic - incidental finding on ALP or X-ray

12. Hearing loss mechanism: CN VIII compression (sensorineural) or ossicular sclerosis (conductive)

13. Pre-bisphosphonate checks: Vitamin D, calcium, renal function, dental assessment

14. Warmth over bone on palpation = hypervascular pagetic bone (pathognomonic sign)

15. Picture frame vertebra = classic spinal X-ray appearance

---

17. References

1. Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet. 2008;372(9633):155-163. doi:10.1016/S0140-6736(08)61223-7

2. Singer FR, Bone HG, Hosking DJ, et al. Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(12):4408-4422. doi:10.1210/jc.2014-2910

3. Ralston SH. Paget's disease of bone. N Engl J Med. 2013;368(7):644-650. doi:10.1056/NEJMcp1204713

4. Hadjipavlou A, Gaitanis I, Katonis P, et al. Paget's disease of the bone and its management. Eur J Cancer Care (Engl). 2001;10(4):239-249. doi:10.1046/j.1365-2354.2001.00273.x

5. van Staa TP, Selby P, Leufkens HG, et al. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res. 2002;17(3):465-471. doi:10.1359/jbmr.2002.17.3.465

6. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353(9):898-908. doi:10.1056/NEJMoa044241

7. Cooper C, Schafheutle K, Dennison E, et al. The epidemiology of Paget's disease in Britain: is the prevalence decreasing? J Bone Miner Res. 1999;14(2):192-197. doi:10.1359/jbmr.1999.14.2.192

8. Cundy T, McAnulty K, Wattie D, et al. Evidence for secular change in Paget's disease. Bone. 1997;20(1):69-71. doi:10.1016/s8756-3282(96)00311-5

9. Barker DJ, Chamberlain AT, Guyer PB, Gardner MJ. Paget's disease of bone: the Lancashire focus. BMJ. 1980;280(6222):1105-1107. doi:10.1136/bmj.280.6222.1105

10. Altman RD, Brown M, Gargano F. Low back pain in Paget's disease of bone. Clin Orthop Relat Res. 1987;(217):152-161.

11. Siris ES, Ottman R, Flaster E, Kelsey JL. Familial aggregation of Paget's disease of bone. J Bone Miner Res. 1991;6(5):495-500. doi:10.1002/jbmr.5650060511

12. Ralston SH, Layfield R. Pathogenesis of Paget disease of bone. Calcif Tissue Int. 2012;91(2):97-113. doi:10.1007/s00223-012-9599-0

13. Tiegs RD, Lohse CM, Wollan PC, Melton LJ. Long-term trends in the incidence of Paget's disease of bone. Bone. 2000;27(3):423-427. doi:10.1016/s8756-3282(00)00333-1

14. Cundy T, Rutland MD, Naot D. Evolution of Paget's disease of bone in New Zealand: continuing decline in disease severity. Calcif Tissue Int. 2006;79(1):6-10. doi:10.1007/s00223-006-0035-5

15. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002;70(6):1582-1588. doi:10.1086/340731

16. Ralston SH, Helfrich MH. Are paramyxoviruses involved in Paget's disease? A negative view. Bone. 1999;24(5 Suppl):17S-19S. doi:10.1016/s8756-3282(99)00026-8

17. Kurihara N, Hiruma Y, Zhou H, et al. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest. 2007;117(1):133-142. doi:10.1172/JCI28267

18. Roodman GD, Windle JJ. Paget disease of bone. J Clin Invest. 2005;115(2):200-208. doi:10.1172/JCI24281

19. Rea SL, Walsh JP, Ward L, et al. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype. J Bone Miner Res. 2006;21(7):1136-1145. doi:10.1359/jbmr.060405

20. Albagha OM, Visconti MR, Alonso N, et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat Genet. 2010;42(6):520-524. doi:10.1038/ng.562

21. Rebel A, Malkani K, Basle M, Bregeon C. Osteoclast ultrastructure in Paget's disease. Calcif Tissue Res. 1976;20(2):187-199. doi:10.1007/BF02546411

22. Vellenga CJ, Pauwels EK, Bijvoet OL. Untreated Paget disease of bone studied by scintigraphy. Radiology. 1984;153(3):799-805. doi:10.1148/radiology.153.3.6387792

23. Siris ES. Paget's disease of bone. J Bone Miner Res. 1998;13(7):1061-1065. doi:10.1359/jbmr.1998.13.7.1061

24. Merkow RL, Lane JM. Paget's disease of bone. Orthop Clin North Am. 1990;21(1):171-189.

25. Khairi MR, Altman RD, DeRosa GP, et al. Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. Ann Intern Med. 1977;87(6):656-663. doi:10.7326/0003-4819-87-6-656

26. Grundy M. Fractures of the femur in Paget's disease of bone. Their etiology and treatment. J Bone Joint Surg Br. 1970;52(2):252-263.

27. Guyer PB, Shepherd DF. Paget's disease of the lumbar spine. Br J Radiol. 1980;53(634):286-290. doi:10.1259/0007-1285-53-634-286

28. Alvarez L, Guañabens N, Peris P, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res. 1995;10(3):458-465. doi:10.1002/jbmr.5650100318

29. Smith SE, Murphey MD, Motamedi K, et al. From the archives of the AFIP. Radiologic spectrum of Paget disease of bone and its complications with pathologic correlation. Radiographics. 2002;22(5):1191-1216. doi:10.1148/radiographics.22.5.g02se281191

30. Vellenga CJ, Pauwels EK, Bijvoet OL, et al. Bone scintigraphy in Paget's disease treated with combined calcitonin and diphosphonate. Metab Bone Dis Relat Res. 1984;5(4):197-202. doi:10.1016/0221-8747(84)90009-x

31. Moore TE, King AR, Kathol MH, et al. Sarcoma in Paget disease of bone: clinical, radiologic, and pathologic features in 22 cases. AJR Am J Roentgenol. 1991;156(6):1199-1203. doi:10.2214/ajr.156.6.2028863

32. Singer FR, Bone HG, Hosking DJ, et al. Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(12):4408-4422. doi:10.1210/jc.2014-2910

33. Lau AW, Pringle RM. Paget's disease and total hip replacement. J Bone Joint Surg Br. 1993;75(3):408-411. doi:10.1302/0301-620X.75B3.8496209

34. Siris ES, Canfield RE, Jacobs TP. Paget's disease of bone. Bull N Y Acad Med. 1980;56(3):285-304.

35. Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res. 2007;22(1):142-148. doi:10.1359/jbmr.061001

36. Miller PD, Brown JP, Siris ES, et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med. 1999;106(5):513-520. doi:10.1016/s0002-9343(99)00060-1

37. Singer FR, Fredericks RS, Minkin C. Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance. Arthritis Rheum. 1980;23(10):1148-1154. doi:10.1002/art.1780231011

38. Reddy SV, Singer FR, Roodman GD. Bone marrow mononuclear cells from patients with Paget's disease contain measles virus nucleocapsid messenger ribonucleic acid that has mutations in a specific region of the sequence. J Clin Endocrinol Metab. 1995;80(7):2108-2111. doi:10.1210/jcem.80.7.7608264

39. Haibach H, Farrell C, Dittrich FJ. Neoplasms arising in Paget's disease of bone: a study of 82 cases. Am J Clin Pathol. 1985;83(5):594-600. doi:10.1093/ajcp/83.5.594

40. Hosking DJ, Bijvoet OL. Disorders of bone and mineral metabolism in patients with Paget's disease. Baillieres Clin Endocrinol Metab. 1997;11(1):145-172. doi:10.1016/s0950-351x(97)80569-5

41. Tan A, Goodman K, Walker A, et al. Long-term randomized trial of intensive versus symptomatic management in Paget's disease of bone: the PRISM-EZ study. J Bone Miner Res. 2017;32(6):1165-1173. doi:10.1002/jbmr.3066

42. Hartman JT, Dohn DF. Paget's disease of the spine with cord or nerve-root compression. J Bone Joint Surg Am. 1966;48(6):1079-1084.

43. Cundy HR, Gamble G, Wattie D, et al. Paget's disease of bone in New Zealand: continued decline in disease severity. Calcif Tissue Int. 2004;75(5):358-364. doi:10.1007/s00223-004-0281-z

44. Tan A, Goodman K, Walker A, et al. Long-term randomized trial of intensive versus symptomatic management in Paget's disease of bone: the PRISM-EZ study. J Bone Miner Res. 2017;32(6):1165-1173. doi:10.1002/jbmr.3066